<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Fifteen adult patients undergoing allogeneic bone marrow transplantation (BMT) received <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> (CSP) as prophylaxis of <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft versus host disease</z:e> (GVHD) </plain></SENT>
<SENT sid="1" pm="."><plain>In our patients eleven were <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e>, and four were severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Twelve patients were HLA-matched, and three were one locus mismatched </plain></SENT>
<SENT sid="3" pm="."><plain>Three patients received CSP only, twelve received CSP and short term <z:chebi fb="0" ids="44185">methotrexate</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>Seven patients had <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD, but GVHD over Grade II were seen in only 3 patients who were transplanted from HLA-one locus mismatched donor </plain></SENT>
<SENT sid="5" pm="."><plain>7 patients had <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD </plain></SENT>
<SENT sid="6" pm="."><plain>CSP were given intravenously at 3-5 mg/kg, starting 1 day before BMT </plain></SENT>
<SENT sid="7" pm="."><plain>From about day 30, CSP was given orally </plain></SENT>
<SENT sid="8" pm="."><plain>CSP concentrations when patients were given orally were lower in patients who had <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD </plain></SENT>
<SENT sid="9" pm="."><plain>Although <z:hpo ids='HP_0000822'>hypertension</z:hpo> and water retention were seen in 8 patients, and <z:hpo ids='HP_0000082'>renal dysfunction</z:hpo> was seen in 3 patients, the side effects of CSP were mild and transient </plain></SENT>
<SENT sid="10" pm="."><plain>There were no correlations between serum concentrations and the side effects of CSP </plain></SENT>
<SENT sid="11" pm="."><plain>Three patients had the disturbance of hematopoiesis </plain></SENT>
<SENT sid="12" pm="."><plain>Ten of fifteen patients are alive at median follow-up of 18.5 months (8-41 months) after BMT </plain></SENT>
</text></document>